Market closed
Vaxart/$VXRT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxart
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Ticker
$VXRT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
105
ISIN
US92243A2006
Website
Vaxart Metrics
BasicAdvanced
$115M
-
-$0.27
-
-
Price and volume
Market cap
$115M
52-week high
$1.04
52-week low
$0.29
Average daily volume
1.9M
Financial strength
Current ratio
0.636
Quick ratio
0.589
Long term debt to equity
30.65
Total debt to equity
45.072
Interest coverage (TTM)
-19.25%
Management effectiveness
Return on assets (TTM)
-28.90%
Return on equity (TTM)
-114.74%
Valuation
Price to revenue (TTM)
2.312
Price to book
2.53
Price to tangible book (TTM)
3.05
Price to free cash flow (TTM)
-3.249
Growth
Revenue change (TTM)
433.43%
Earnings per share change (TTM)
-48.78%
3-year revenue growth (CAGR)
365.13%
3-year earnings per share growth (CAGR)
-24.76%
What the Analysts think about Vaxart
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vaxart stock.
Vaxart Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vaxart Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vaxart News
AllArticlesVideos
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
GlobeNewsWire·3 days ago
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewsWire·4 days ago
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vaxart stock?
Vaxart (VXRT) has a market cap of $115M as of May 19, 2025.
What is the P/E ratio for Vaxart stock?
The price to earnings (P/E) ratio for Vaxart (VXRT) stock is 0 as of May 19, 2025.
Does Vaxart stock pay dividends?
No, Vaxart (VXRT) stock does not pay dividends to its shareholders as of May 19, 2025.
When is the next Vaxart dividend payment date?
Vaxart (VXRT) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxart?
Vaxart (VXRT) does not currently have a Beta indicator.